Enzyme inhibition or removal may prevent or treat ischemic retinopathy

Jan 13, 2011
Dr. Mohamed Al-Shabrawey, MCG assistant professor of oral biology, anatomy and ophthalmology, found that the inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina. Credit: Phil Jones, Campus Photographer

The inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina, Medical College of Georgia researchers say.

Ischemic retinopathy is characterized by uncontrolled formation of new in the , and is seen in diseases such as and retinopathy of prematurity. While this blood vessel formation, called neovascularization, can benefit ischemic and , it is bad in the retina, where new vessels are dysfunctional and bleed, usually ending in retinal detachment.

Retinal neovascularization is controlled by a balancing act between pigment epithelium derived factor, the "good guy," and its nemesis, vascular endothelial growth factor.

"We wanted to learn how the disruption of that balance occurs and how to prevent it," said Dr. Mohamed Al-Shabrawey, Assistant Professor of Oral Biology, Anatomy and Ophthalmology and corresponding author of the study published online in Diabetes.

Al-Shabrawey studied an inflammatory pathway that has been shown to induce expression of the bad growth factor. In that pathway, the enzyme 12-lipoxygenase converts arachidonic acid, which helps regulate neovascularization, into the product 12-hydroxyeicosatetraenoic acid, or 12-HETE. He hypothesized that 12-HETE is linked to retinal neovascularization.

The study found a significant increase in the expression of the enzyme and production of 12-HETE in humans with advanced-stage diabetic retinopathy and in animals with induced ischemic retinopathy.

Al-Shabrawey also treated retinal Müller cells in vitro with 12-HETE. He found this increased the amount of and decreased pigment epithelium derived factor, disrupting the balance and leading to neovascularization.

Using this finding, Al-Shabrawey's team found that treating the animals with an enzyme inhibitor or inducing ischemic retinopathy in animals lacking the enzyme restored that balance and inhibited neovascularization.

"This led us to conclude that if we can target or inhibit this enzyme's pathway, we might be able to prevent or treat diseases of ischemic retinopathy," Al-Shabrawey said.

While this study focused on an end stage of the disease, the next step is to study how inhibiting the enzyme will affect earlier stages of vascular dysfunction.

Explore further: Texas hospital isolates patient for Ebola tests

Provided by Medical College of Georgia

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Blocking protein may prevent blinding disease

Sep 16, 2009

Blocking a protein that battles infection may help thwart a common cause of vision loss in chronic diseases such as diabetes, Medical College of Georgia researchers say.

Recommended for you

Is Australia prepared for Ebola?

2 hours ago

Australia needs to be proactive about potential disease outbreaks like Ebola and establish a national centre for disease control.

Dallas hospital confirms first Ebola case in US

7 hours ago

A patient at a Dallas hospital has tested positive for Ebola, the first case of the disease to be diagnosed in the United States, federal health officials announced Tuesday.

First case of Ebola diagnosed in US

9 hours ago

The United States has diagnosed its first case of the deadly Ebola virus in a man who became infected in Liberia and traveled to Texas, US health officials said Tuesday.

Study finds acupuncture does not improve chronic knee pain

10 hours ago

Among patients older than 50 years with moderate to severe chronic knee pain, neither laser nor needle acupuncture provided greater benefit on pain or function compared to sham laser acupuncture, according to a study in the ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

ironjustice
not rated yet Jan 13, 2011
"The Environment of the Lipoxygenase Iron Binding Site Explored with Novel Hydroxypyridinone Iron Chelators"